Clinical Trials
14 trialsNCT03357757 2025-06-26
LATENT
AHS Cancer Control Alberta
Phase 2 Completed
NCT01817751 2024-07-17
Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
Virginia Commonwealth University
Phase 2 Completed
NCT00879437 2021-07-21
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Baylor College of Medicine
Phase 2 Completed
NCT00414310 2019-05-21
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01182285 2018-05-16
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00867672 2016-08-31
DECIDER
University Hospital Freiburg
Phase 2 Completed
NCT00302159 2016-08-18
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01695122 2016-02-23
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
Instituto do Cancer do Estado de São Paulo
Phase 2 Completed
NCT00634205 2015-02-12
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
European Lung Cancer Working Party
Phase 2 Completed
NCT00759824 2015-02-12
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
European Lung Cancer Working Party
Phase 2 Completed
NCT00382590 2012-08-07
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00326170 2012-06-15
Phase II 5-Azacytidine Plus VPA Plus ATRA
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00404326 2006-11-28
Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer
National Institute of Cancerología
Phase 2 Completed
NCT00404508 2006-11-28
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
National Institute of Cancerología
Phase 2 Completed